Methamphetamine Laboratory Disclosure Clause Samples

The Methamphetamine Laboratory Disclosure clause requires parties to a real estate transaction to disclose whether the property has ever been used as a site for manufacturing methamphetamine. In practice, this clause obligates the seller to inform the buyer if the property was previously involved in meth production, which may include providing documentation or answering specific questions during the sale process. Its core function is to protect buyers from unknowingly purchasing properties that may pose health risks or require costly remediation due to contamination, thereby ensuring transparency and informed decision-making.
POPULAR SAMPLE Copied 1 times
Methamphetamine Laboratory Disclosure. The parties acknowledge that each Seller of a Colorado Property is required to disclose whether such Seller knows that its Property was previously used as a methamphetamine laboratory. No disclosure is required if such Property was remediated in accordance with state standards and other requirements are fulfilled pursuant to § 25-18.5-102, C.R.S. Purchaser further acknowledges that Purchaser has the right to engage a certified hygienist or industrial hygienist to test whether any of the Properties has ever been used as a methamphetamine laboratory. If Purchaser's test results indicate that a Property has been used as a methamphetamine laboratory, but has not been remediated to meet the standards established by rules of the Colorado State Board of Health promulgated pursuant to § 25-18.5-102, C.R.S., Purchaser shall promptly give written notice to Seller's Representative of the results of the test, and Purchaser may terminate this Agreement.
Methamphetamine Laboratory Disclosure. The parties acknowledge that Seller is required to disclose whether Seller knows that the Property was previously used as a methamphetamine laboratory. No disclosure is required if the Property was remediated in accordance with state standards and other requirements are fulfilled pursuant to § 25-18.5-102, C.R.S. Buyer further acknowledges that Buyer has the right to engage a certified hygienist or industrial hygienist to test whether the Property has ever been used as a methamphetamine laboratory. In the event that the Property has been used as a methamphetamine laboratory, Buyer may deliver written notice to Seller, on or before Closing, to terminate this Contract.
Methamphetamine Laboratory Disclosure. If the Property is residential, and Seller knows that methamphetamine was ever manufactured, processed, cooked, disposed of, used, or stored at the Property, Seller is required to disclose such fact. No disclosure is required if the Property was remediated in accordance with state standards and other requirements are fulfilled pursuant to § 25-18.5- 102, C.R.S. Purchaser further acknowledges that Purchaser has the right to engage a certified hygienist or industrial hygienist to test whether the Property has ever been used as a methamphetamine laboratory. If the Property has been used as a methamphetamine laboratory, Purchaser may deliver written notice to Seller, on or before Closing, to terminate this Contract.
Methamphetamine Laboratory Disclosure. The parties acknowledge that Sellers are required to disclose whether Sellers know that the Property was previously used as a methamphetamine laboratory. Sellers herein state that Sellers are not aware of any such use of the Property. No disclosure is required if the Property was remediated in accordance with state standards and other requirements are fulfilled pursuant to C.R.S. 25-18.5-102. Purchaser further acknowledges that the Purchaser has the right to engage a certified hygienist or industrial hygienist to test whether the Property has ever been used as a methamphetamine laboratory. In the event that the Property has been used as a methamphetamine laboratory, Purchaser may deliver written notice to Sellers of such, on or before the Closing Date, and this agreement shall be terminated.

Related to Methamphetamine Laboratory Disclosure

  • Nepotism No employee shall be awarded a position where he/she is to be directly supervised by a member of his/her immediate family. “

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.